XTalks

MARCH 13, 2024

Related: Transforming Eye Care: Innovating New Glaucoma and Dry Eye Disease Treatments — Featuring Pierre Simon, VP Marketing, Sight Sciences – Xtalks Life Science Podcast Ep. Hormone-based therapeutics aim to delay glaucoma progression by enhancing estrogen’s potential protective effects.

Gene Therapy 111

Gene Therapy Gene Life Science DNA 111

XTalks

SEPTEMBER 17, 2020

Symptoms and Etiology: Caused by an overproduction of growth hormone, acromegaly primarily affects adults. By reducing the amount of growth hormone in the blood, progressive enlargement of bones should be slowed. By reducing the amount of growth hormone in the blood, progressive enlargement of bones should be slowed.

Trials 98

Trials Gene Hormones Clinical Trials 98

XTalks

MAY 27, 2022

Treatment resistance has been in part attributed to mutation in the ESR1 gene which plays a significant role in sexual and reproductive health. The ESR1 gene has also been detected in recurrent local and metastatic cancer cells. which is encoded by the ESR1 gene in humans. What is Elacestrant and How Does It Work? Future Scope.

Clinical Trials 98

Clinical Trials Clinical Trials Trials Gene 98

XTalks

NOVEMBER 20, 2023

AstraZeneca has won its first-in-class approval for its AKT inhibitor Truqap (capivasertib) in combination with Faslodex (fulvestrant) for treating patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer.

HR 98

HR FDA Approval Gene Trials 98

XTalks

MARCH 22, 2021

As a leader in life sciences, diagnostics and applied chemical markets, it is looking to grow its cancer diagnostics pipeline. The tool analyzes the differential expression of over 90 genes to distinguish between 50 tumors types and subtypes. Both of Biotheranostics’ diagnostics are PCR-based gene expression tests.

Life Science 110

Life Science Development Marketing Gene Expression 110

pharmaphorum

DECEMBER 23, 2020

It has been a year dominated by the pandemic and many life sciences research projects were put on hold as big pharma turned its attention to vaccines and therapies. NT-814 is a non-hormonal drug that works on the neurokinin (NK) 1,3 receptor antagonist, thus treating the vasomotor symptoms associated with the menopause.

Marketing 96

Marketing Gene Gene Silencing Drugs 96

XTalks

FEBRUARY 6, 2023

Erythropoietin is a hormone that is produced by the kidneys and signals the body to make red blood cells. By inhibiting oxygen-sensing prolyl hydroxylase enzymes, Jesduvroq stabilizes hypoxia-inducible factors, and this can lead to the transcription of erythropoietin and other genes that help correct anemia.

FDA Approval 97

FDA Approval Clinical Trials Clinical Trials Trials 97

XTalks

JUNE 20, 2022

Hereditary ATTR has an autosomal dominant pattern of inheritance and is caused by point mutations in the transthyretin ( TTR ) gene that codes for the transthyretin transport protein found in the plasma and cerebrospinal fluid.

FDA Approval 98

FDA Approval Protein Genetics RNA 98

The Pharma Data

MARCH 31, 2022

A significant part of these investments will be made for enhanced capacities in biotechnology, further strengthening the company’s cell and gene therapy production as well as in the expansion of its manufacturing site in Berkeley, USA. Germany will remain an important strategic manufacturing location for the company.

Production 52

Production Manufacturing Hormones Gene Therapy 52

pharmaphorum

JUNE 8, 2022

Zilebesiran (formerly ALN-AGT) is one of a new breed of gene-silencing drugs that are intended to treat common, chronic diseases with infrequent dosing to boost compliance with treatment.

Gene Silencing 52

Gene Silencing Drugs Medicine Regulation 52

XTalks

FEBRUARY 3, 2023

In addition, about 40 percent of these cases involve mutations in the ESR1 gene. Current treatments include hormonal therapies that focus on blocking the function of the estrogen receptor, curbing its production or degrading the receptor itself.

Clinical Trials 97

Clinical Trials Clinical Trials FDA Approval Trials 97

XTalks

MAY 23, 2024

For example, pediatric growth hormone deficiency (PGHD) affects approximately one in 3,500 to one in 10,000 children. Existing therapeutic options for PGHD consist of injectable formulations of recombinant human growth hormone (rhGH), administered subcutaneously either on a daily or weekly basis.

Clinical Trials 52

Clinical Trials Clinical Trials Hormones Trials 52

XTalks

AUGUST 2, 2023

5) Ibrance (palbociclib) Ibrance is a chemotherapy drug indicated for hormone receptor positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer. It is a CDK 4/6 inhibitor that is taken in combination with other hormonal therapies to stop the growth of cancer and healthy cells. billion in 2022.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

XTalks

FEBRUARY 5, 2024

In the dynamic landscape of oncology therapeutics, understanding the trends and performances of leading drugs is crucial for stakeholders across the healthcare and life sciences sectors. Alecensa is approved in Japan for the additional indication of recurrent or refractory ALK fusion gene-positive anaplastic large-cell lymphoma.

FDA Approval 101

FDA Approval Drugs Sales Development 101

The Pharma Data

MARCH 11, 2021

Speaking at the virtual Capital Markets Day on Wednesday, CEO Werner Baumann emphasized Bayer’s long-term growth perspectives: “Bayer is a leading life science company, uniquely positioned at the intersection of health and nutrition – with attractive prospects for growth, earnings and cash flow.”

Sales 52

Sales Gene Therapy Marketing Gene 52

XTalks

AUGUST 15, 2023

Akeega is a dual-action tablet (DAT) that contains the company’s androgen receptor-targeting hormone therapy Zytiga (abiraterone acetate) and PARP inhibitor (poly [ADP-ribose] polymerase inhibitor) niraparib. Lynparza received FDA approval in May 2020 for mCRPC in patients with homologous recombinational repair ( HRR ) gene mutations.

FDA Approval 52

FDA Approval Gene Hormones Drugs 52

XTalks

JUNE 27, 2022

The BRAF gene regulates cell growth, proliferation and apoptosis. Mutations in this gene can contribute to the growth of different cancer cells, and many patients with cancer carry BRAF mutations. Tafinlar + Mekinist is also the first of its kind approved for use in pediatric patients.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Gene 52

The Pharma Data

FEBRUARY 21, 2022

Bayer’s research and development pipeline continues to grow as the company is building on its existing competencies, such as the expertise around small molecules, while expanding into new modalities, including cell and gene therapies.

Radiology 52

Radiology Cardiology Development Production 52

The Pharma Data

DECEMBER 9, 2020

The Chinese biopharmaceutical industry is growing in leaps and bounds, but there is still a huge unmet need when it comes to getting patients access to the breakthrough therapeutic modalities and platforms like RNAi, cell and gene therapy and others. A solution could be at hand with Overland Pharmaceuticals.

In-Vivo 52

In-Vivo In-Vitro Antibody Development 52

The Pharma Data

APRIL 11, 2023

Another key focus at Bayer is on innovative precision oncology treatments, with an approved TRK inhibitor exclusively designed to treat tumors that have an NTRK gene fusion, the oncogenic driver of tumor growth and spread. About Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition.

Research 40

Research Clinical Trials Clinical Trials Trials 40

XTalks

FEBRUARY 5, 2024

In the dynamic landscape of oncology therapeutics, understanding the trends and performances of leading drugs is crucial for stakeholders across the healthcare and life sciences sectors. Alecensa is approved in Japan for the additional indication of recurrent or refractory ALK fusion gene-positive anaplastic large-cell lymphoma.

FDA Approval 52

FDA Approval Drugs Sales Development 52

Pharmaceutical Technology

JANUARY 22, 2023

One of these is MCT8 deficiency, a condition caused by a mutation in the MCT8 gene, which affects one in 700,000 males. The mutation leads to disordered thyroid hormone transport, which causes patients to experience intellectual and motor disabilities. T3 is a major hormone in the blood that regulates thyroid levels.

Drugs 317

Drugs Gene Hormones Clinical Trials 317

Pharmaceutical Technology

APRIL 24, 2023

Biologics are costly to produce and sell, and the more recent modalities, such as cell and gene therapies, can be difficult to manufacture. There are fewer sites for cell and gene therapies and vaccines – 90 companies with 127 facilities, as per GlobalData figures.

Contract Manufacturing 130

Contract Manufacturing Manufacturing Protein Sales 130

XTalks

NOVEMBER 26, 2024

Xtandi is also prescribed for metastatic prostate cancer that continues to respond to hormone therapy. This latest approval makes Xtandi the first androgen receptor signaling inhibitor approved for use without gonadotropin-releasing hormone therapy in non-metastatic castration-sensitive prostate cancer.

Sales 105

Sales FDA Approval Drugs Marketing 105

XTalks

MARCH 5, 2025

In the pivotal Phase III VERIFY study, researchers evaluated rusfertide, a firstinclass investigational hepcidin mimetic peptide therapeutic designed to mimic the natural hormone that regulates iron, to see if it could reduce the need for regular blood removals (phlebotomies). The competitive landscape in polycythemia vera is intensifying.

Trials 59

Trials Clinical Trials Clinical Trials Hormones 59

XTalks

FEBRUARY 27, 2025

The trial was conducted on patients whose tumors have developed mutations in the estrogen receptor 1 ( ESR1 ) gene, a known contributor to endocrine therapy resistance that leads to relapses and rapid disease progression, limiting treatment options and worsening survival prospects.

Trials 59

Trials HR Clinical Trials Clinical Trials 59